Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 9, 2026
- ADC Therapeutics reported third-quarter net product revenue of $21.0 million and net loss of $25.3 million. Its October 2026 restructuring included an $86.6 million PIPE and extends expected cash runway into 2029.
- 10-Q report · filed Nov 9, 2026
- ADC Therapeutics reported that Phase 3 LOTIS-5 showed significantly improved progression-free survival with ZYNLONTA plus rituximab versus R-GemOx in 420 patients; median PFS was 6.14 months versus 4.73 months.
The audio replay and transcript follow the call.